Sirolimus inhibits key events of restenosis in vitro/ex vivo: evaluation of the clinical relevance of the data by SI/MPL- and SI/DES-ratio's

Sirolimus inhibits key events of restenosis in vitro/ex vivo: evaluation of the clinical relevance of the data by SI/MPL- and SI/DES-ratio's

<p>Abstract</p> <p>Background</p> <p>Sirolimus (SRL, Rapamycin) has been used successfully to inhibit restenosis both in drug eluting stents (DES) and after systemic application. The current study reports on the effects of SRL in various human in vitro/ex vivo models an...

Full description

Bibliographic Details
Main Authors: Kountides Margaratis, Gschwendt Jürgen, Braun Jürgen, Baur Regine, von Müller Lutz, Fahlisch Felicitas, Müller Fabian, Zellmann Svenja, Voisard Rainer, Hombach Vinzenz, Kamenz Joachim
Format: Article
Language:English
Published: BMC 2007-05-01
Series:BMC Cardiovascular Disorders
Online Access:http://www.biomedcentral.com/1471-2261/7/15

Internet

http://www.biomedcentral.com/1471-2261/7/15

Similar Items